BioStock: Cyxone has gathered new force

Biotech company Cyxone has had a busy summer. In June Tara Heitner took over as the new CEO and has since strengthened the team and the internal therapeutic expertise through the recruitment of Christin Arrhenius Bokedal as Head of Development and presented Maarten Kraan and Rikard Holmdahl as the company’s senior scientific advisors. BioStock reached out to the two senior advisors to hear their views on their new positions.

Read the full article about Cyxone at

This is a press release from BioStock - Connecting Innovation & Capital.

About Us

Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of immune disorders such as multiple sclerosis (MS), rheumatoid arthritis (RA) and Covid-19. The company’s drug portfolio is based on two technological pillars in the form of orally available molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders. Cyxone’s technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in clinical phase I program and Rabeximod for RA and Covid-19 in clinical phase II program. Cyxone’s Certified Adviser on the Nasdaq First North Growth Market is Mangold Fondkommission AB, +46 (0)8-503 015 50,


Quick facts

BioStock: Cyxone has gathered new force
Tweet this